Overview

XELOX for Metastatic Breast Cancer

Status:
Completed

Trial end date:
2006-11-01

Target enrollment:

Participant gender:

Summary

Both capecitabine and oxaliplatin have single agent activity in breast cancer. The combination has improved activity in other solid tumors. This study seeks to assess the activity of the combination in breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

University of Wisconsin, Madison

Collaborator:

Sanofi

Treatments:

Capecitabine
Oxaliplatin